Validity And Reliability of The Incremental Shuttle Walk Test In Type 2 Diabetes Mellitus
Launched by ILAYDA KAYAPINAR · Jul 19, 2024
Trial Information
Current as of August 19, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This clinical trial is studying a test called the Incremental Shuttle Walk Test (ISWT) to see how well it works for people with type 2 diabetes. The goal is to check if this walking test is reliable and valid for measuring how well someone can walk and how their health is doing. Participants will first have their health information recorded and then take the ISWT and another walking test, with a break in between. A week later, they will come back to do the ISWT again to see if the results are consistent.
To be eligible for this trial, participants should be between 65 and 74 years old, have a specific level of blood sugar control (measured by HbA1c between 6.5 and 11), and be able to walk on their own. Unfortunately, people with certain health issues, like uncontrolled diabetes or serious heart and lung conditions, as well as those who are pregnant or have severe problems with their muscles or nerves, will not be able to participate. This study is still in the planning stages and has not started recruiting participants yet.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • HbA1c between 6.5 and 11
- • No mental problems
- • Able to walk independently
- Exclusion Criteria:
- • Lack of co-operation
- • Uncontrolled diabetes,
- • Patients with uncontrolled hypotension or hypertension
- • Unstable cardiovascular and pulmonary conditions
- • Having vertigo and various vestibular system disorders
- • Those with severe neurological or severe respiratory diseases
- • Patients with major musculoskeletal problems
- • Pregnant women
About Ilayda Kayapinar
Ilayda Kayapinar is a dedicated clinical trial sponsor focused on advancing medical research and innovation. With a strong commitment to ethical standards and regulatory compliance, the organization actively collaborates with healthcare professionals, researchers, and institutions to design and implement clinical trials that aim to evaluate new therapies and interventions. Leveraging a robust network and expertise in clinical operations, Ilayda Kayapinar strives to enhance patient outcomes and contribute to the scientific community through rigorous data collection and analysis, ultimately fostering the development of breakthrough treatments in various therapeutic areas.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, , Turkey
Patients applied
Trial Officials
Melis USUL, RA
Principal Investigator
Istanbul Kent Universty
Gülenay YILDIRIM, RA
Principal Investigator
Istanbul Galata Universty
Gökşen KURAN ASLAN, Prof
Study Director
Istanbul Universty-Cerrahpaşa
Semiramis Özyılmaz, Assoc Prof
Study Director
Bezmaialem Foundation University
Muhammed TUNÇ, Asst Prof
Principal Investigator
Bezmaialem Foundation University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported